A New Look at Old Drugs: The Evolving Debate on Neuropathic Pain Management A recent perspective article in *Pain Medicine* critically examines the comparative effectiveness of pregabalin and duloxetine, two cornerstone medications for painful diabetic neuropathy. The analysis highlights the current evidence landscape, noting the limitations of head-to-head trials and the variable individual patient responses to each therapy. The central argument pivots from a simple drug-versus-drug comparison to a forward-looking call for research into rational combination therapies.

The Cost Conundrum: Weighing Value in Fibromyalgia Pharmacotherapy A new decision-analytical model published in JAMA Network Open evaluates the cost-effectiveness of three common medications—pregabalin, duloxetine, and milnacipran—against the older, generic drug amitriptyline for treating moderate to severe fibromyalgia. The study provides a rigorous economic framework to assess not just clinical efficacy but also the long-term financial impact on healthcare systems, offering a data-driven perspective on value-based prescribing for this complex chronic pain condition.